Genetic and molecular markers of urothelial premalignancy and malignancy

Scandinavian Journal of Urology and Nephrology, Supplement

Volumn 34, Issue 205, 2000, Pages 82-93

  Cordon Cardo, Carlos ^a   Cote, Richard J ^b   Sauter, Guido ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Genetic markers; Malignancy; Molecular markers; Premalignancy; Urothelium

Indexed keywords

PROTEIN P53;

ANTIGEN EXPRESSION; APOPTOSIS; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER GROWTH; CANCER SCREENING; CELL DEATH; CHROMOSOME 9; CHROMOSOME ABERRATION; CONFERENCE PAPER; DISEASE MARKER; EARLY DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENETIC ANALYSIS; GENETIC MARKER; HUMAN; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; RECURRENT DISEASE; TUMOR SUPPRESSOR GENE; URINE CYTOLOGY; BLADDER; BLADDER TUMOR; CARCINOMA IN SITU; CELL TRANSFORMATION; DISEASE COURSE; GENETICS; PATHOLOGY; REVIEW; TRANSITIONAL CELL CARCINOMA;

CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; GENETIC MARKERS; HUMANS; PRECANCEROUS CONDITIONS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0034353135     PISSN: 03008886     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655900750169338     Document Type: Conference Paper

References (13)

1. Reuter VE, Melamed MR. The lower urinary tract. In: Sternberg SS, ed. Diagnostic surgical pathology. New York: Raven Press, 1989: 1355.
2. Zhang Z-F, Steineck G. Epidemiology and etiology of bladder cancer. In: Raghavan D, Scher HI, Leibel SA, Lange P, eds. Principles and practice of genitourinary oncology. Philadelphia, PA: J.B. Lippincott Company, 1996.
3. Mostofi FK, Sesterhenn IA. Pathology of epithelial tumors and carcinoma in situ of bladder. Prog Clin Biol Res 1984; 62: 55-74.
4. Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet 1993; 324: 469-71.
5. Spruck CH, Ohneseit PE, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994; 54: 784-8.
6. Johansson SL, Cohen SM. Pathology of bladder cancer. In: Raghavan D, Scher HI, Leibel SA, Lange P, eds. Principles and practice of genitourinary oncology. Philadelphia, PA: J. B. Lippincott Company, 1997: 207-13.
7. Koss L Diagnostic cytology and its histopathologic bases, 4th edn. Philadelphia, PA: J. B. Lippincott Company, 1992.
8. Kiemeney LA, Witjes JA, Heijbroek RP, Debruyne FM, Verbeek AL. Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer. Eur J Cancer 1994; 30: 1621-5.
9. Igawa M, Urakami S, Shirakawa H. A mapping of histology and cell proliferation in human bladder cancer: an immunohistochemical study. Hiroshima J Med Sci 1995; 44: 93-7.
10. Cordon-Cardo C. Mutation of cell cycle regulators: Biological and clinical implications for human neoplasias. Am J Pathol 1995; 147: 545-60.
11. Cote RJ, Chatterjee SJ. Molecular determinants of outcome in bladder cancer. Cancer J Sci Am 1999; 5: 2-15.
12. Cordon-Cardo C, Sheinfeld J, Dalbagni G. Genetic studies and molecular markers of bladder cancer. Semin Surg Oncol 1997; 13: 319-27.
13. Orntoft T, Wolf H. Molecular alterations in bladder cancer. Urol Res 1998; 26: 223-33.